Roth Capital Estimates ChromaDex’s Q2 Earnings (NASDAQ:CDXC)

ChromaDex Co. (NASDAQ:CDXC) – Stock analysts at Roth Capital issued their Q2 2025 earnings per share (EPS) estimates for ChromaDex in a report issued on Tuesday, November 5th. Roth Capital analyst S. Mcgowan anticipates that the company will post earnings of $0.01 per share for the quarter. The consensus estimate for ChromaDex’s current full-year earnings is $0.02 per share. Roth Capital also issued estimates for ChromaDex’s Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.03 EPS and FY2026 earnings at $0.14 EPS.

Several other research firms have also recently weighed in on CDXC. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Friday. HC Wainwright boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Finally, Roth Mkm boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday.

ChromaDex Stock Performance

NASDAQ CDXC opened at $6.50 on Friday. ChromaDex has a twelve month low of $1.32 and a twelve month high of $7.08. The stock has a market capitalization of $496.47 million, a PE ratio of 650.65 and a beta of 1.88. The stock has a 50-day simple moving average of $3.83 and a 200 day simple moving average of $3.33.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The business had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. During the same quarter in the previous year, the firm earned ($0.01) EPS.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

Large investors have recently modified their holdings of the stock. Miracle Mile Advisors LLC bought a new stake in shares of ChromaDex in the 2nd quarter valued at approximately $27,000. The Manufacturers Life Insurance Company bought a new stake in ChromaDex during the 2nd quarter worth approximately $31,000. Merriman Wealth Management LLC bought a new stake in ChromaDex during the 2nd quarter worth approximately $32,000. Lazard Asset Management LLC bought a new stake in ChromaDex during the 1st quarter worth approximately $43,000. Finally, SG Americas Securities LLC bought a new stake in ChromaDex during the 1st quarter worth approximately $54,000. 15.41% of the stock is currently owned by institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.